GO:0090120 lysosome to ER cholesterol transport: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090120 describes the directed movement of cholesterol from the lysosome to the endoplasmic reticulum (ER), a process essential for cellular cholesterol homeostasis.
• Lysosome-ER membrane contact sites (MCS) serve as the primary platform for cholesterol transfer, mediated by proteins such as STARD3, VAPB, and LIMP-2.
• This transport pathway is critical for mTORC1 signaling and is dysregulated in Niemann-Pick type C disease, leading to aberrant growth signaling.
• Cholesterol transfer via ER contacts also mediates lysosome damage repair, highlighting its role in organelle quality control.
• Key genes involved include NPC1, NPC2, STARD3, VAPB, and LIMP-2 (SCARB2), which are frequently studied using CRISPR knockout and knock-in models.
• Dysregulation of lysosome to ER cholesterol transport is implicated in metabolic liver disease, inflammatory bowel disease, and neurodegeneration.
Description
Cholesterol is an essential lipid that must be precisely distributed among cellular membranes to maintain organelle function and signaling. The lysosome serves as a central hub for cholesterol processing, receiving cholesterol from low-density lipoprotein (LDL) and other sources. From the lysosome, cholesterol must be transported to the endoplasmic reticulum (ER), where it is sensed and redistributed to other membranes. This directed movement is defined by the Gene Ontology term GO:0090120, lysosome to ER cholesterol transport. Understanding this process is fundamental to lipid cell biology and has broad implications for metabolic and neurodegenerative diseases. The transport is not a simple diffusion but relies on specialized protein machinery at membrane contact sites between the lysosome and ER. These contact sites facilitate the efficient and regulated transfer of cholesterol, often in concert with other lipids. Defects in this pathway lead to cholesterol accumulation in lysosomes, a hallmark of lysosomal storage disorders such as Niemann-Pick type C. Moreover, emerging evidence links lysosome to ER cholesterol transport to mTORC1 signaling, autophagy, and lysosomal membrane repair, underscoring its integrative role in cellular homeostasis. Researchers studying this process aim to identify the molecular players, understand their regulation, and develop therapeutic strategies for related diseases.
lysosome to ER cholesterol transport At A Glance
| GO ID | GO:0090120 |
|---|---|
| GO term | lysosome to ER cholesterol transport |
| Ontology | biological_process |
| Synonym | lysosome to endoplasmic reticulum cholesterol transport |
| Major function | Transfer of cholesterol from lysosomes to the ER for cellular cholesterol homeostasis |
| Related cellular components | Lysosomal membrane, ER membrane, membrane contact sites |
| Key molecular players | NPC1, NPC2, STARD3, VAPB, LIMP-2 (SCARB2) |
| Associated diseases | Niemann-Pick type C, metabolic liver disease, inflammatory bowel disease |
| Research methods | CRISPR knockout/knock-in, live-cell imaging, lipidomics, proximity labeling |
What Is GO:0090120?
GO:0090120, lysosome to ER cholesterol transport, is defined as the directed movement of cholesterol, cholest-5-en-3-beta-ol, or cholesterol-containing compounds from the lysosome to the endoplasmic reticulum. This is a biological process that ensures cholesterol, after being liberated from LDL or synthesized, is transferred from the lysosomal lumen or membrane to the ER for sensing, esterification, or redistribution. The process is distinct from other cholesterol transport routes and is often mediated by membrane contact sites and lipid transfer proteins.
Why Is lysosome to ER cholesterol transport Important in Cell Biology?
Lysosome to ER cholesterol transport is a central node in cellular cholesterol homeostasis. It ensures that cholesterol derived from lysosomal degradation of LDL is delivered to the ER, where it regulates sterol regulatory element-binding protein (SREBP) pathways and maintains membrane lipid composition. Disruption of this transport leads to lysosomal cholesterol accumulation, impaired mTORC1 signaling, and defective lysosomal repair, which are linked to diseases such as Niemann-Pick type C, metabolic liver disease, and inflammatory bowel disease. Thus, understanding this process is critical for developing therapies targeting cholesterol-related disorders.
• Maintains cellular cholesterol homeostasis by delivering lysosomal cholesterol to the ER for sensing and redistribution.
• Supports mTORC1 signaling, which controls cell growth and metabolism, as shown in Niemann-Pick type C models.
• Enables lysosome membrane repair after damage, a process dependent on ER cholesterol transfer.
• Dysregulation contributes to lysosomal storage disorders, particularly Niemann-Pick type C disease.
• Implicated in metabolic liver diseases, including non-alcoholic fatty liver disease, through autophagy and lipid droplet interactions.
• Links to inflammatory bowel disease via autophagy and gut microbiota interactions.
• Provides targets for therapeutic intervention in cholesterol trafficking disorders.
• Serves as a model for studying membrane contact site biology and lipid transfer proteins.
• Essential for proper autophagic flux and lysosomal function.
• Highlights the role of lysosome-ER contact sites in organelle communication.
What Happens During lysosome to ER cholesterol transport?
Cholesterol egress from the lysosome
In simple terms: Cholesterol must first exit the lysosome before it can reach the ER.
Cholesterol enters the lysosome via LDL degradation and is exported by the coordinated action of NPC1 and NPC2. NPC2 binds cholesterol in the lumen and transfers it to NPC1, a membrane protein that facilitates its insertion into the lysosomal membrane. Mutations in NPC1 or NPC2 cause cholesterol to accumulate in lysosomes, as seen in Niemann-Pick type C disease. This step is the initial and rate-limiting stage of lysosome to ER cholesterol transport.
Formation of lysosome-ER membrane contact sites
In simple terms: The lysosome and ER come close together to form a bridge for cholesterol transfer.
Membrane contact sites (MCS) between the lysosome and ER are specialized regions where the two organelles are tethered within 10-30 nm. These sites are enriched in proteins such as STARD3, VAPB, and LIMP-2, which facilitate cholesterol transfer. STARD3, a cholesterol-binding protein, interacts with VAPB on the ER to form a tether, while LIMP-2 (SCARB2) is part of the lysosomal side of the contact site. These MCS provide a platform for efficient lipid exchange without membrane fusion.
Cholesterol transfer at contact sites
In simple terms: Cholesterol is handed directly from the lysosome to the ER at the contact site.
At the MCS, cholesterol is transferred from the lysosomal membrane to the ER membrane. This process may involve lipid transfer proteins such as STARD3, which can bind and shuttle cholesterol. The transfer is driven by cholesterol gradients and is regulated by the availability of cholesterol and the presence of acceptor proteins in the ER. The ER then distributes cholesterol to other organelles or esterifies it for storage.
Cholesterol sensing and downstream signaling
In simple terms: Once in the ER, cholesterol is sensed and triggers cellular responses.
After reaching the ER, cholesterol is sensed by the SREBP pathway and by mTORC1 at the lysosome-ER interface. In Niemann-Pick type C, defective transport leads to aberrant mTORC1 activation, which drives abnormal growth signaling. Proper cholesterol delivery to the ER also supports lysosomal membrane repair after damage, a process that requires ER-derived cholesterol. Thus, this transport step integrates cholesterol homeostasis with growth control and organelle quality control.
Regulation by autophagy and lipid droplets
In simple terms: Autophagy and lipid droplets influence how much cholesterol moves from lysosomes to the ER.
Autophagy delivers lipids to lysosomes and can modulate cholesterol availability for transport to the ER. In liver disease, the interplay between autophagy, lipid droplets, and lysosomes affects cholesterol trafficking and contributes to steatosis. These regulatory inputs ensure that lysosome to ER cholesterol transport adapts to cellular metabolic demands.
Key Genes Involved in GO:0090120 lysosome to ER cholesterol transport
The following genes and proteins are central to lysosome to ER cholesterol transport, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NPC1 | Lysosomal membrane protein that exports cholesterol from the lysosome | Mutations cause Niemann-Pick type C; target for knockout studies |
| NPC2 | Luminal cholesterol-binding protein that transfers cholesterol to NPC1 | Defects lead to cholesterol accumulation; used in point mutation models |
| STARD3 | Cholesterol-binding protein at lysosome-ER contact sites | Key mediator of cholesterol transfer; knockout reduces transport |
| VAPB | ER membrane protein that tethers to STARD3 | Forms contact sites; knockdown disrupts transport |
| LIMP-2 (SCARB2) | Lysosomal membrane protein in contact sites | Part of STARD3-VAPB-dependent contact sites; knockout affects cholesterol egress |
| SREBF2 | ER transcription factor regulating cholesterol synthesis | Senses ER cholesterol; knockout alters homeostasis |
| mTOR | Kinase that senses cholesterol at lysosome-ER contacts | Dysregulated in NPC; used in signaling studies |
| RAB7 | Late endosomal/lysosomal GTPase | Regulates lysosome positioning and contact sites |
| ATG5 | Autophagy-related protein | Links autophagy to cholesterol trafficking |
| ATG7 | Autophagy-related protein | Modulates lipid availability for transport |
| LC3B (MAP1LC3B) | Autophagosome marker | Used to monitor autophagy-lipid crosstalk |
| ABCA1 | Cholesterol efflux transporter | Affects cellular cholesterol distribution |
| ABCG1 | Cholesterol efflux transporter | Related to cholesterol homeostasis |
| CYP46A1 | Cholesterol 24-hydroxylase | Brain cholesterol metabolism; may influence transport |
| APOE | Lipid transport protein | Modulates cholesterol trafficking in brain and liver |
| LDLR | LDL receptor | Delivers cholesterol to lysosomes for transport |
| PCSK9 | Regulator of LDLR degradation | Affects lysosomal cholesterol supply |
| GRAMD1A | ER cholesterol transfer protein | Potential role in ER cholesterol sensing |
How Is lysosome to ER cholesterol transport Regulated?
Lysosome to ER cholesterol transport is regulated at multiple levels. The availability of cholesterol in the lysosome, controlled by NPC1 and NPC2, sets the rate of transport. Membrane contact sites are dynamically regulated by proteins such as STARD3 and VAPB, whose expression and interactions can be modulated by cholesterol levels. mTORC1 signaling at the lysosome-ER interface responds to cholesterol and can feedback on transport. Autophagy influences the delivery of lipids to lysosomes, thereby affecting substrate availability. Additionally, lysosomal damage triggers accelerated cholesterol transfer for membrane repair, linking transport to organelle quality control. These regulatory mechanisms ensure that cholesterol homeostasis is maintained under varying metabolic conditions.
lysosome to ER cholesterol transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NPC1 | Niemann-Pick type C | Knockout iPSC-derived neurons; point mutation knock-in mice |
| NPC2 | Niemann-Pick type C | Knockout HeLa cells; overexpression in patient fibroblasts |
| STARD3 | Cholesterol trafficking defects | Knockout HeLa cells; tagged knock-in for live imaging |
| VAPB | ALS and cholesterol transport | Knockout motor neurons; point mutation knock-in |
| LIMP-2 (SCARB2) | Lysosomal dysfunction | Knockout HEK293T; overexpression for contact site studies |
Niemann-Pick type C disease
Niemann-Pick type C (NPC) is a lysosomal storage disorder caused by mutations in NPC1 or NPC2, leading to defective lysosome to ER cholesterol transport. Cholesterol accumulates in lysosomes, causing neurodegeneration, hepatosplenomegaly, and early death. Studies show that ER-lysosome contacts enable cholesterol sensing by mTORC1, and their dysfunction drives aberrant growth signaling in NPC. This highlights the pathway as a therapeutic target.
Metabolic liver disease
Autophagy and lipid droplets intersect with lysosome to ER cholesterol transport in hepatic metabolism. Dysregulation contributes to non-alcoholic fatty liver disease and other metabolic disorders. Therapeutic regulation of autophagy may restore cholesterol trafficking and improve liver function.
Inflammatory bowel disease
Autophagy modulates gut microbiota and inflammatory responses in inflammatory bowel disease (IBD). Cholesterol transport from lysosomes to the ER may influence immune cell function and intestinal homeostasis. Defects in this pathway could exacerbate inflammation.
Neurodegeneration
Cholesterol is critical for brain function, and its transport from lysosomes to the ER is essential for neuronal survival. Defects in this pathway, as seen in NPC, lead to progressive neurodegeneration. Understanding the molecular players may reveal new targets for Alzheimer's and related dementias.
From lysosome to ER cholesterol transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does NPC1 loss impair lysosome to ER cholesterol transport? | NPC1 knockout HeLa or iPSC-derived neurons |
| How does STARD3 mediate cholesterol transfer? | STARD3 knockout with rescue by wild-type or mutant |
| What is the role of VAPB in contact site formation? | VAPB knockout and tagged knock-in for proximity labeling |
| Can overexpression of NPC2 rescue cholesterol accumulation? | NPC2 overexpression in patient fibroblasts |
| Does mTORC1 sense cholesterol at lysosome-ER contacts? | mTOR knockout or point mutation in NPC models |
| How does autophagy regulate cholesterol transport? | ATG5 or ATG7 knockout in liver cells |
How to Study the lysosome to ER cholesterol transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Live-cell imaging with BODIPY-cholesterol | Real-time cholesterol transfer | Visualizing lysosome to ER transport |
| Proximity labeling (APEX/BioID) | Protein composition of contact sites | Identifying new regulators |
| Lipidomics (LC-MS) | Cholesterol and ester levels | Quantifying transport efficiency |
| CRISPR knockout screen | Genes affecting cholesterol transport | Discovery of novel players |
| Immunofluorescence | Colocalization of proteins | Confirming contact site formation |
| FRET-based cholesterol sensors | Cholesterol concentration at membranes | Measuring ER cholesterol |
| RNA-seq | Transcriptional changes | Assessing SREBP pathway activation |
| Co-immunoprecipitation | Protein-protein interactions | Validating STARD3-VAPB binding |
Live-cell imaging of cholesterol transport
Fluorescent cholesterol analogs (e.g., BODIPY-cholesterol) and GFP-tagged proteins (STARD3, VAPB) allow real-time visualization of cholesterol transfer from lysosomes to ER. This method reveals dynamics of contact sites and transport rates.
Proximity labeling and proteomics
APEX or BioID tagging of lysosomal or ER proteins identifies components of membrane contact sites. Proteomic analysis of contact site fractions reveals novel regulators of cholesterol transport.
Lipidomics and cholesterol quantification
Mass spectrometry-based lipidomics quantifies cholesterol and cholesteryl esters in subcellular fractions. This measures the efficiency of transport and identifies accumulation in lysosomes.
CRISPR screening for regulators
Genome-wide CRISPR knockout screens with cholesterol-sensitive reporters identify genes required for lysosome to ER transport. Hits are validated by imaging and biochemical assays.
How CRISPR Can Be Used to Study GO:0090120 lysosome to ER cholesterol transport
Knockout
CRISPR knockout of NPC1, NPC2, STARD3, or VAPB in cell lines such as HeLa or HEK293T abolishes or reduces lysosome to ER cholesterol transport. These models are used to study cholesterol accumulation, mTORC1 signaling, and lysosomal repair.
Point Mutation
Point mutations in NPC1 (e.g., p.P691S) or NPC2 model patient-specific defects. CRISPR knock-in of these mutations in iPSCs or cell lines recapitulates disease phenotypes and allows testing of pharmacological chaperones.
Knock-in
Tagged knock-in of STARD3 or VAPB with fluorescent or proximity labeling tags enables live imaging and proteomic analysis of contact sites. This approach reveals dynamic regulation of cholesterol transport.
Overexpression
Overexpression of NPC1, NPC2, or STARD3 can enhance cholesterol transport and rescue defects in patient cells. This is useful for structure-function studies and therapeutic development.
How EDITGENE Supports lysosome to ER cholesterol transport Research
Researchers studying lysosome to ER cholesterol transport-related genes often need to determine whether a candidate gene is causally involved in cholesterol trafficking, contact site formation, or disease progression. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for lysosome to ER cholesterol transport research.
Frequently Asked Questions About lysosome to ER cholesterol transport
What is lysosome to ER cholesterol transport?
It is the biological process defined by GO:0090120, where cholesterol moves from the lysosome to the endoplasmic reticulum, often at membrane contact sites.
What genes are involved in lysosome to ER cholesterol transport?
Key genes include NPC1, NPC2, STARD3, VAPB, and LIMP-2 (SCARB2), which mediate cholesterol export and contact site formation.
How does cholesterol get from lysosomes to the ER?
Cholesterol exits the lysosome via NPC1/NPC2 and is transferred at lysosome-ER contact sites, possibly via STARD3 and other lipid transfer proteins.
What diseases are linked to lysosome to ER cholesterol transport?
Niemann-Pick type C disease, metabolic liver disease, inflammatory bowel disease, and neurodegeneration.
What is the role of NPC1 in cholesterol transport?
NPC1 is a lysosomal membrane protein that exports cholesterol from the lysosome; mutations cause Niemann-Pick type C.
How is lysosome to ER cholesterol transport studied?
Using live-cell imaging, lipidomics, proximity labeling, and CRISPR screens.
What is the function of STARD3 in cholesterol transport?
STARD3 is a cholesterol-binding protein at lysosome-ER contact sites that facilitates cholesterol transfer.
Can CRISPR be used to study lysosome to ER cholesterol transport?
Yes, CRISPR knockout, knock-in, and overexpression models are widely used to dissect gene function in this pathway.
What is the significance of mTORC1 in lysosome to ER cholesterol transport?
mTORC1 senses cholesterol at lysosome-ER contacts, and its dysregulation contributes to aberrant growth signaling in Niemann-Pick type C.
How does lysosome to ER cholesterol transport relate to autophagy?
Autophagy delivers lipids to lysosomes and influences cholesterol availability for transport to the ER.
Conclusion
Lysosome to ER cholesterol transport (GO:0090120) is a fundamental cellular process that ensures cholesterol homeostasis and supports signaling, membrane repair, and organelle function. Dysregulation of this pathway is implicated in severe diseases, including Niemann-Pick type C, metabolic liver disease, and inflammatory bowel disease. Continued research using CRISPR-based models and advanced imaging will uncover new therapeutic targets and deepen our understanding of lipid trafficking.
References
- 1. Byrnes K et al.. 2022. Therapeutic regulation of autophagy in hepatic metabolism.. Acta Pharm Sin B 12(1):33-49 PMID: 35127371
- 2. Larabi A et al.. 2020. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.. Autophagy 16(1):38-51 PMID: 31286804
- 3. Lim CY et al.. 2019. ER-lysosome contacts enable cholesterol sensing by mTORC1 and drive aberrant growth signalling in Niemann-Pick type C.. Nat Cell Biol 21(10):1206-1218 PMID: 31548609
- 4. Filali-Mouncef Y et al.. 2022. The ménage à trois of autophagy, lipid droplets and liver disease.. Autophagy 18(1):50-72 PMID: 33794741
- 5. Radulovic M et al.. 2022. Cholesterol transfer via endoplasmic reticulum contacts mediates lysosome damage repair.. EMBO J 41(24):e112677 PMID: 36408828
- 6. Soccio RE et al.. 2004. Intracellular cholesterol transport.. Arterioscler Thromb Vasc Biol 24(7):1150-60 PMID: 15130918
- 7. Pfisterer SG et al.. 2016. LDL-cholesterol transport to the endoplasmic reticulum: current concepts.. Curr Opin Lipidol 27(3):282-7 PMID: 27054443
- 8. Rudnik S et al.. 2024. The lysosomal lipid transporter LIMP-2 is part of lysosome-ER STARD3-VAPB-dependent contact sites.. J Cell Sci 137(22) PMID: 39370902
